In line with recent work on the etiology and treatment of neurological diseases such as Alzheimer’s, Parkinson’s, Huntington’s, epilepsy, Rett’s syndrome, and neuropsychiatric disorders such as depression, bipolar, anxiety-related, schitzophrenia, and addiction (Autry & Monteggia, 2012; Hu & Russek, 2008), the nSTART model is consistent with clinical treatments for impaired cognitive function that implicate an important role for BDNF. Here, BDNF is linked to depressive symptom measurement.